|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...678910111213141516...156157» |
- | rHIgM22 / Acorda
Trial completion: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Dec 2, 2017
P1, N=27, Completed, Sponsor: Acorda Therapeutics
Active, not recruiting --> Completed
- |||| Plivensia (sirukumab) / J&J
Trial primary completion date: SIRROUND-LTE: Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 (clinicaltrials.gov) - Nov 30, 2017
P3, N=1820, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Nov 2019 --> Apr 2018
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: HORTOCI: Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. (clinicaltrials.gov) - Nov 30, 2017
P2, N=20, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Trial primary completion date: Nov 2019 --> Apr 2018 Trial primary completion date: Jun 2016 --> Dec 2015
- |||| Litfulo (ritlecitinib) / Pfizer
Enrollment open: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate (clinicaltrials.gov) - Nov 30, 2017
P2a, N=60, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jun 2016 --> Dec 2015 Active, not recruiting --> Recruiting
- Enrollment closed: Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) (clinicaltrials.gov) - Nov 30, 2017
P1, N=48, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date: Niclosamide With Etanercept in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 30, 2017
P1/2, N=110, Recruiting, Sponsor: Faiq Gorial
Recruiting --> Active, not recruiting Initiation date: Apr 2017 --> Aug 2017
- |||| evobrutinib (M2951) / EMD Serono
Trial completion: MS200527-0081: Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 29, 2017
P2a, N=65, Completed, Sponsor: EMD Serono Research & Development Institute, Inc.
Initiation date: Apr 2017 --> Aug 2017 Active, not recruiting --> Completed
- || Trial primary completion date: VEGA Prospective Kiel (clinicaltrials.gov) - Nov 27, 2017
P=N/A, N=100, Recruiting, Sponsor: Aesculap AG
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Apr 2018
- talacotuzumab (JNJ-56022473) / J&J
Enrollment change, Trial initiation date, Trial withdrawal: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 27, 2017
P1b, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Sep 2017 --> Apr 2018 N=49 --> 0 | Initiation date: Oct 2016 --> Jun 2017 | Not yet recruiting --> Withdrawn
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Trial completion: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Nov 27, 2017
P3, N=26, Completed, Sponsor: Catalyst Pharmaceuticals, Inc.
N=49 --> 0 | Initiation date: Oct 2016 --> Jun 2017 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- |||| opigolix (ASP1707) / Astellas
Trial completion: A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate (clinicaltrials.gov) - Nov 27, 2017
P2a, N=72, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Active, not recruiting --> Completed
- | prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment closed, Enrollment change: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Nov 27, 2017
P2a, N=32, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=42 --> 32
- | Trial completion, Phase classification: Insight Kids: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Nov 27, 2017
P=N/A, N=43, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=42 --> 32 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A
- | Biomarker, Enrollment closed, Enrollment change, Trial primary completion date: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (clinicaltrials.gov) - Nov 21, 2017
P4, N=115, Active, not recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed | Phase classification: P4 --> PN/A Recruiting --> Active, not recruiting | N=200 --> 115 | Trial primary completion date: Dec 2017 --> Jun 2018
- | Enrollment closed, Trial primary completion date: T1REDEEM: Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes (clinicaltrials.gov) - Nov 21, 2017
P=N/A, N=290, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | N=200 --> 115 | Trial primary completion date: Dec 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: HORTOCI: Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. (clinicaltrials.gov) - Nov 21, 2017
P2, N=20, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: May 2015 --> Jun 2016
- Rebif (human IFN-?-1a) / EMD Serono
Enrollment change, Trial termination, Trial primary completion date: MESTRE-MS: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 21, 2017
P=N/A, N=2, Terminated, Sponsor: Merck KGaA
Recruiting --> Completed | Trial primary completion date: May 2015 --> Jun 2016 N=133 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2017; Delay in site selection and recruitment.
- Plivensia (sirukumab) / J&J
Enrollment change, Trial withdrawal: Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica (clinicaltrials.gov) - Nov 20, 2017
P3, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=133 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2017; Delay in site selection and recruitment. N=150 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Myasterix (CV-MG01) / CuraVac
Trial initiation date: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - Nov 20, 2017
P2/3, N=66, Not yet recruiting, Sponsor: CuraVac
N=150 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jun 2017 --> Jan 2018
- | Trial completion, Video: Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=60, Completed, Sponsor: Dokuz Eylul University
Initiation date: Jun 2017 --> Jan 2018 Recruiting --> Completed
- | Trial completion: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=30, Completed, Sponsor: University Hospital of Ferrara
Recruiting --> Completed Recruiting --> Completed
- Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=0, Withdrawn, Sponsor: Medtronic Diabetes
Recruiting --> Completed N=20 --> 0 | Initiation date: Sep 2017 --> Jan 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Jul 2016
- ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Trial completion, Trial primary completion date: A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - Nov 18, 2017
P3, N=0, Completed, Sponsor: Kissei Pharmaceutical Co., Ltd.
N=20 --> 0 | Initiation date: Sep 2017 --> Jan 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Oct 2017
- ||||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Trial completion, Enrollment change, Trial primary completion date: VOLTAIRE-RAext: Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 18, 2017
P3, N=430, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Oct 2017 Active, not recruiting --> Completed | N=350 --> 430 | Trial primary completion date: Aug 2017 --> Nov 2017
- ||| Trial completion, Phase classification: Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=414, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=350 --> 430 | Trial primary completion date: Aug 2017 --> Nov 2017 Active, not recruiting --> Completed | Phase classification: P3 --> PN/A
- ||| Enrollment closed: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 17, 2017
P2, N=62, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A Recruiting --> Active, not recruiting
- | Trial completion, Phase classification, Trial primary completion date: A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=36, Completed, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | Trial primary completion date: Mar 2017 --> Jun 2017
- | Trial completion, Trial initiation date, Trial primary completion date: Effects of Web-Based Health Information on Risk Behavior for Youth With Type 1 Diabetes in College (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=138, Completed, Sponsor: Boston Children
Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | Trial primary completion date: Mar 2017 --> Jun 2017 Not yet recruiting --> Completed | Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Oct 2017 --> May 2017
- ||||||| atorvastatin / Generic mfg.
Trial completion: AdDIT: Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (clinicaltrials.gov) - Nov 14, 2017
P3, N=443, Completed, Sponsor: University of Cambridge
Not yet recruiting --> Completed | Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Oct 2017 --> May 2017 Active, not recruiting --> Completed
- ||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) (clinicaltrials.gov) - Nov 14, 2017
P3, N=730, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Trial completion, Enrollment change, Trial primary completion date: HPV-kind: Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease (clinicaltrials.gov) - Nov 13, 2017
P4, N=135, Completed, Sponsor: N.M. Wulffraat
Active, not recruiting --> Completed Recruiting --> Completed | N=330 --> 135 | Trial primary completion date: Sep 2016 --> Jan 2015
- || Enrollment closed: BICAFMS: Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=470, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=330 --> 135 | Trial primary completion date: Sep 2016 --> Jan 2015 Recruiting --> Active, not recruiting
- | Trial completion, Phase classification, Trial primary completion date: Extended Follow-Up After Islet Transplantation in T1D (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=75, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | Phase classification: P3 --> PN/A | Trial primary completion date: Jul 2018 --> Jul 2017
- | Trial initiation date: Edu4U: The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=178, Not yet recruiting, Sponsor: University of Louisville
Enrolling by invitation --> Completed | Phase classification: P3 --> PN/A | Trial primary completion date: Jul 2018 --> Jul 2017 Initiation date: Aug 2017 --> Aug 2018
- | Trial completion, Trial primary completion date: Metabolic Risk and Life Style Factors in Women With Previous Gestational Diabetes Mellitus (GDM) (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=210, Completed, Sponsor: University of Southern Denmark
Initiation date: Aug 2017 --> Aug 2018 Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017
- || LAPS-Insulin (HM12460A) / Hanmi
Enrollment change, Trial primary completion date: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Nov 8, 2017
P1, N=86, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017 N=48 --> 86 | Trial primary completion date: Feb 2014 --> Jul 2014
- ||| Trial completion, Enrollment change: Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=100, Completed, Sponsor: Vastra Gotaland Region
N=48 --> 86 | Trial primary completion date: Feb 2014 --> Jul 2014 Active, not recruiting --> Completed | N=130 --> 100
- | Trial completion, Trial primary completion date: Impact of Different Types of Exercise Training on Biochemical Markers of Insulin-dependent Patients (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=28, Completed, Sponsor: Federal University of Rio Grande do Sul
Active, not recruiting --> Completed | N=130 --> 100 Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2017
- | Enrollment closed, Trial primary completion date: SSENIOR: Pruritus and Pemphigoid in Nursing Home Patients (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=126, Active, not recruiting, Sponsor: M.F. Jonkman
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- || Orencia (abatacept) / BMS
Trial primary completion date, Real-world evidence, Real-world: Real-world Clinical Efficacy of Abatacept in the T3 Data Registry (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=200, Completed, Sponsor: Arthritis Northwest PLLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Mar 2012 --> Nov 2016
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion: CogMS-Ext: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=46, Completed, Sponsor: Clinique Neuro-Outaouais
Trial primary completion date: Mar 2012 --> Nov 2016 Active, not recruiting --> Completed
- | Biomarker, Trial completion, Enrollment change: Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=74, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Active, not recruiting --> Completed Recruiting --> Completed | N=110 --> 74
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Anti-CD20 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 6, 2017
P1/2, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=110 --> 74 No longer recruiting --> Completed
- | Trial primary completion date: Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=10, Recruiting, Sponsor: Clinique Neuro-Outaouais
No longer recruiting --> Completed Trial primary completion date: Jan 2017 --> Jan 2018
- || Remicade (infliximab) / J&J
Enrollment change: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=150, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Trial primary completion date: Jan 2017 --> Jan 2018 N=338 --> 150
- | Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Trial primary completion date: TARGET-DLE: Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus (clinicaltrials.gov) - Oct 31, 2017
P2, N=25, Active, not recruiting, Sponsor: University of Leeds
N=338 --> 150 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- ||| Litfulo (ritlecitinib) / Pfizer
Enrollment closed: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate (clinicaltrials.gov) - Oct 31, 2017
P2a, N=70, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- | Trial primary completion date: Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy (clinicaltrials.gov) - Oct 30, 2017
P=N/A, N=2, Terminated, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Dec 2015
- | Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial termination: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 30, 2017
P2, N=76, Terminated, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Terminated; Wk 52 primary endpoint results would be unaffected by follow-up data so trial was discontinued prior to wk 104. No safety data was collected after wk 52.
- | Trial completion: Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 30, 2017
P2, N=15, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
No safety data was collected after wk 52. Recruiting --> Completed